Modern management of non-chemotherapy drug-induced agranulocytosis: a monocentric cohort study of 90 cases and review of the literature
Background: The present study reports a monocentric experience of 90 drug-induced agranulocytosis cases and discusses their management, in particular the role of hematopoietic growth factors. Methods: Data from 90 patients with drug-induced agranulocytosis who met the criteria of the IAAAS group and...
Saved in:
Published in: | European journal of internal medicine Vol. 13; no. 5; pp. 324 - 328 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Netherlands
Elsevier B.V
01-08-2002
Elsevier |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Background: The present study reports a monocentric experience of 90 drug-induced agranulocytosis cases and discusses their management, in particular the role of hematopoietic growth factors.
Methods: Data from 90 patients with drug-induced agranulocytosis who met the criteria of the IAAAS group and of Bénichou and Solal-Celigny [Nouv Rev Fr Hematol 1993; 33: 257.] were retrospectively reviewed. All cases were extracted from a cohort study of the Hopitaux Universitaires de Strasbourg, France. Data were specifically analyzed with regard to the use of hematopoietic growth factors (in 42 patients).
Results: Mean patient age was 63 (range 17–95) years and the sex ratio (M/F) was 0.39. An underlying disease was present in 37% of the patients. Antibiotics (25%), antithyroid drugs (23%), and antiaggregative platelet agents (16%) were the most frequent causative drugs. Main clinical features included isolated fever (41%), septicemia or septic shock (31%), and pneumonia (10%). Mean neutrophil count was 0.13 (range 0–0.46)×10
9/l. Outcome was favorable in 98% of patients. The mean durations of hematological recovery (neutrophil count over 1.5×10
9/l), antibiotic therapy, and hospitalization was 8.5 (range 2–21) days, 9.2 (range 2–21) days, and 10.5 (range 3–23) days, respectively. All patients were treated with broad-spectrum antibiotics and 42 patients with hematopoietic growth factors. In these 42 patients, the mean durations for hematological recovery, antibiotic therapy, and hospitalization were significantly reduced at: 6.3 (range 2–16) days, 7.1 (range 2–16) days, and 9.1 (range 3–23) days, respectively (all
P<0.05).
Conclusions: The present study shows that new causative drugs are emerging (antibiotics, antithyroid, and antiaggregative platelet agents), that drug-induced agranulocytosis remains typically a serious accident with severe sepsis, and that modern management with broad spectrum antibiotics and hematopoietic growth factors may reduce the mortality. |
---|---|
AbstractList | Background: The present study reports a monocentric experience of 90 drug-induced agranulocytosis cases and discusses their management, in particular the role of hematopoietic growth factors. Methods: Data from 90 patients with drug-induced agranulocytosis who met the criteria of the IAAAS group and of Be´nichou and Solal-Celigny [Nouv Rev Fr Hematol 1993; 33: 257.] were retrospectively reviewed. All cases were extracted from a cohort study of the Hopitaux Universitaires de Strasbourg, France. Data were specifically analyzed with regard to the use of hematopoietic growth factors (in 42 patients). Results: Mean patient age was 63 (range 17–95) years and the sex ratio (M/F) was 0.39. An underlying disease was present in 37% of the patients. Antibiotics (25%), antithyroid drugs (23%), and antiaggregative platelet agents (16%) were the most frequent causative drugs. Main clinical features included isolated fever (41%), 9 septicemia or septic shock (31%), and pneumonia (10%). Mean neutrophil count was 0.13 (range 0–0.46)310 / l. Outcome was favorable 9 in 98% of patients. The mean durations of hematological recovery (neutrophil count over 1.5310 / l), antibiotic therapy, and hospitalization was 8.5 (range 2–21) days, 9.2 (range 2–21) days, and 10.5 (range 3–23) days, respectively. All patients were treated with broad-spectrum antibiotics and 42 patients with hematopoietic growth factors. In these 42 patients, the mean durations for hematological recovery, antibiotic therapy, and hospitalization were significantly reduced at: 6.3 (range 2–16) days, 7.1 (range 2–16) days, and 9.1 (range 3–23) days, respectively (all P,0.05). Conclusions: The present study shows that new causative drugs are emerging (antibiotics, antithyroid, and antiaggregative platelet agents), that drug-induced agranulocytosis remains typically a serious accident with severe sepsis, and that modern management with broad spectrum antibiotics and hematopoietic growth factors may reduce the mortality. BACKGROUND: The present study reports a monocentric experience of 90 drug-induced agranulocytosis cases and discusses their management, in particular the role of hematopoietic growth factors. METHODS: Data from 90 patients with drug-induced agranulocytosis who met the criteria of the IAAAS group and of Bénichou and Solal-Celigny [Nouv Rev Fr Hematol 1993; 33: 257.] were retrospectively reviewed. All cases were extracted from a cohort study of the Hopitaux Universitaires de Strasbourg, France. Data were specifically analyzed with regard to the use of hematopoietic growth factors (in 42 patients). RESULTS: Mean patient age was 63 (range 17-95) years and the sex ratio (M/F) was 0.39. An underlying disease was present in 37% of the patients. Antibiotics (25%), antithyroid drugs (23%), and antiaggregative platelet agents (16%) were the most frequent causative drugs. Main clinical features included isolated fever (41%), septicemia or septic shock (31%), and pneumonia (10%). Mean neutrophil count was 0.13 (range 0-0.46)x10(9)/l. Outcome was favorable in 98% of patients. The mean durations of hematological recovery (neutrophil count over 1.5x10(9)/l), antibiotic therapy, and hospitalization was 8.5 (range 2-21) days, 9.2 (range 2-21) days, and 10.5 (range 3-23) days, respectively. All patients were treated with broad-spectrum antibiotics and 42 patients with hematopoietic growth factors. In these 42 patients, the mean durations for hematological recovery, antibiotic therapy, and hospitalization were significantly reduced at: 6.3 (range 2-16) days, 7.1 (range 2-16) days, and 9.1 (range 3-23) days, respectively (all P<0.05). CONCLUSIONS: The present study shows that new causative drugs are emerging (antibiotics, antithyroid, and antiaggregative platelet agents), that drug-induced agranulocytosis remains typically a serious accident with severe sepsis, and that modern management with broad spectrum antibiotics and hematopoietic growth factors may reduce the mortality. Background: The present study reports a monocentric experience of 90 drug-induced agranulocytosis cases and discusses their management, in particular the role of hematopoietic growth factors. Methods: Data from 90 patients with drug-induced agranulocytosis who met the criteria of the IAAAS group and of Bénichou and Solal-Celigny [Nouv Rev Fr Hematol 1993; 33: 257.] were retrospectively reviewed. All cases were extracted from a cohort study of the Hopitaux Universitaires de Strasbourg, France. Data were specifically analyzed with regard to the use of hematopoietic growth factors (in 42 patients). Results: Mean patient age was 63 (range 17–95) years and the sex ratio (M/F) was 0.39. An underlying disease was present in 37% of the patients. Antibiotics (25%), antithyroid drugs (23%), and antiaggregative platelet agents (16%) were the most frequent causative drugs. Main clinical features included isolated fever (41%), septicemia or septic shock (31%), and pneumonia (10%). Mean neutrophil count was 0.13 (range 0–0.46)×10 9/l. Outcome was favorable in 98% of patients. The mean durations of hematological recovery (neutrophil count over 1.5×10 9/l), antibiotic therapy, and hospitalization was 8.5 (range 2–21) days, 9.2 (range 2–21) days, and 10.5 (range 3–23) days, respectively. All patients were treated with broad-spectrum antibiotics and 42 patients with hematopoietic growth factors. In these 42 patients, the mean durations for hematological recovery, antibiotic therapy, and hospitalization were significantly reduced at: 6.3 (range 2–16) days, 7.1 (range 2–16) days, and 9.1 (range 3–23) days, respectively (all P<0.05). Conclusions: The present study shows that new causative drugs are emerging (antibiotics, antithyroid, and antiaggregative platelet agents), that drug-induced agranulocytosis remains typically a serious accident with severe sepsis, and that modern management with broad spectrum antibiotics and hematopoietic growth factors may reduce the mortality. |
Author | Schlienger, Jean-Louis Andrès, Emmanuel Dufour, Patrick Alt, Martine Sibilia, Jean Blicklé, Jean-Frédéric Maloisel, Frédéric Brogard, Jean-Marie Kaltenbach, Georges Weber, Jean-Christophe Kurtz, Jean-Emmanuel |
Author_xml | – sequence: 1 givenname: Emmanuel surname: Andrès fullname: Andrès, Emmanuel email: emmanuel.andres@chru-strasbourg.fr organization: Department of Internal Medicine, Service de Médecine Interne, Clinique Médicale B, Hôpitaux Universitaires de Strasbourg, 1 Place de l’Hôpital, 67 091 Strasbourg Cedex, France – sequence: 2 givenname: Frédéric surname: Maloisel fullname: Maloisel, Frédéric organization: Department of Onco-Hematology, Hôpitaux Universitaires of Strasbourg, Strasbourg, France – sequence: 3 givenname: Jean-Emmanuel surname: Kurtz fullname: Kurtz, Jean-Emmanuel organization: Department of Onco-Hematology, Hôpitaux Universitaires of Strasbourg, Strasbourg, France – sequence: 4 givenname: Georges surname: Kaltenbach fullname: Kaltenbach, Georges organization: Department of Geriatrics, Hôpitaux Universitaires of Strasbourg, Strasbourg, France – sequence: 5 givenname: Martine surname: Alt fullname: Alt, Martine organization: Centre de Pharmacovigilance d’Alsace, Strasbourg, France – sequence: 6 givenname: Jean-Christophe surname: Weber fullname: Weber, Jean-Christophe organization: Department of Internal Medicine, Service de Médecine Interne, Clinique Médicale B, Hôpitaux Universitaires de Strasbourg, 1 Place de l’Hôpital, 67 091 Strasbourg Cedex, France – sequence: 7 givenname: Jean surname: Sibilia fullname: Sibilia, Jean organization: Department of Rheumatology, Hôpitaux Universitaires of Strasbourg, Strasbourg, France – sequence: 8 givenname: Jean-Louis surname: Schlienger fullname: Schlienger, Jean-Louis organization: Department of Internal Medicine, Service de Médecine Interne, Clinique Médicale B, Hôpitaux Universitaires de Strasbourg, 1 Place de l’Hôpital, 67 091 Strasbourg Cedex, France – sequence: 9 givenname: Jean-Frédéric surname: Blicklé fullname: Blicklé, Jean-Frédéric organization: Department of Internal Medicine, Service de Médecine Interne, Clinique Médicale B, Hôpitaux Universitaires de Strasbourg, 1 Place de l’Hôpital, 67 091 Strasbourg Cedex, France – sequence: 10 givenname: Jean-Marie surname: Brogard fullname: Brogard, Jean-Marie organization: Department of Internal Medicine, Service de Médecine Interne, Clinique Médicale B, Hôpitaux Universitaires de Strasbourg, 1 Place de l’Hôpital, 67 091 Strasbourg Cedex, France – sequence: 11 givenname: Patrick surname: Dufour fullname: Dufour, Patrick organization: Department of Onco-Hematology, Hôpitaux Universitaires of Strasbourg, Strasbourg, France |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/12144912$$D View this record in MEDLINE/PubMed https://hal.science/hal-03287859$$DView record in HAL |
BookMark | eNqFkcFu1DAQhi1URLeFRwD52B4C4yTe2FxQVQFFWsQBOFuOPdk1SuzFdlrtE_DaON1VOXIaafT9_0jzXZAzHzwS8prBWwZs_e47SN5U6xr4FdTXACB41T0jKyY6WYGoxRlZPSHn5CKlXwCsA2hekHNWs7aVrF6RP1-DxejppL3e4oQ-0zDQcqsyO5xC3mHU-wO1cd5WztvZoKV6G7Wfx2AOOSSX3lNNp-CDKeHoDDVhF2KmKc_2sJRJoEYnTFR7SyPeO3xY1qWaji6X_jxHfEmeD3pM-Oo0L8nPTx9_3N5Vm2-fv9zebCrTcp6rTqIxyIUVsh1kL9taamzlILkG24PpjGxArntsNYLWuhkGzlHoAXomgDfNJbk-9u70qPbRTToeVNBO3d1s1LKDphad4PKeFfbqyO5j-D1jympyyeA4ao9hTooVrOl4U3cF5UfUxJBSxOGpm4FafKlHX2qRoaBWj77UkntzOjH3E9p_qZOgAnw4AlieUl4XVTIOfdHgIpqsbHD_OfEXXOWorA |
CitedBy_id | crossref_primary_10_1016_j_amjmed_2003_08_026 crossref_primary_10_1080_08880018_2016_1234523 crossref_primary_10_1517_14740338_7_4_481 crossref_primary_10_1007_s40801_016_0091_4 crossref_primary_10_1093_qjmed_hcr168 crossref_primary_10_1517_14740338_2012_643866 crossref_primary_10_1016_j_revmed_2015_05_013 crossref_primary_10_30895_2312_7821_2020_8_3_109_122 crossref_primary_10_3390_jcm9061808 crossref_primary_10_1016_j_ejim_2017_08_018 crossref_primary_10_1186_s12872_022_02490_3 crossref_primary_10_3390_jcm8091351 crossref_primary_10_1007_s00228_013_1618_1 crossref_primary_10_1517_14740338_6_3_323 crossref_primary_10_3109_03630269_2010_484791 crossref_primary_10_1002_pds_1542 crossref_primary_10_1111_bcp_15170 crossref_primary_10_12659_AJCR_898028 crossref_primary_10_1111_j_1365_2141_2010_08104_x crossref_primary_10_3390_medicines7030015 crossref_primary_10_1016_j_revmed_2005_06_008 crossref_primary_10_1016_j_bcp_2019_01_011 crossref_primary_10_1097_MJT_0b013e3181a4695f crossref_primary_10_1016_j_lpm_2008_03_013 crossref_primary_10_1517_17425255_2015_985649 crossref_primary_10_1097_MOH_0b013e3282f15fb9 crossref_primary_10_1111_bcpt_12418 crossref_primary_10_1016_j_ejim_2006_07_012 crossref_primary_10_1007_s00106_014_2942_1 crossref_primary_10_2515_therapie_2004096 crossref_primary_10_1097_TEN_0b013e3181942905 crossref_primary_10_1586_ehm_11_12 crossref_primary_10_5937_hpimj1803680C crossref_primary_10_7759_cureus_23226 crossref_primary_10_1080_14740338_2017_1376645 crossref_primary_10_1177_0897190014546115 crossref_primary_10_1002_jcph_498 crossref_primary_10_2169_internalmedicine_48_2093 crossref_primary_10_1007_s00228_015_1895_y crossref_primary_10_2165_00002512_200421070_00002 crossref_primary_10_3390_jcm6100092 |
Cites_doi | 10.1016/0248-8663(96)80745-4 10.1001/archinte.159.19.2366 10.1093/ageing/28.3.325 10.1002/(SICI)1096-8652(199803)57:3<206::AID-AJH4>3.0.CO;2-Z 10.1089/thy.1999.9.29 10.1093/qjmed/94.8.423 10.1002/pds.2630020706 10.4269/ajtmh.1999.60.573 10.1592/phco.19.4.299.30941 10.1016/S0002-9343(02)01064-1 10.1001/archinte.159.4.369 10.1016/S0248-8663(00)80002-8 10.1046/j.1365-2125.2000.00132.x 10.1111/j.1365-2141.1991.tb08042.x 10.1001/archinte.1992.00400190095018 10.1200/JCO.1996.14.6.1957 |
ContentType | Journal Article |
Copyright | 2002 Elsevier Science B.V. Distributed under a Creative Commons Attribution 4.0 International License |
Copyright_xml | – notice: 2002 Elsevier Science B.V. – notice: Distributed under a Creative Commons Attribution 4.0 International License |
DBID | NPM AAYXX CITATION 7X8 1XC |
DOI | 10.1016/S0953-6205(02)00085-7 |
DatabaseName | PubMed CrossRef MEDLINE - Academic Hyper Article en Ligne (HAL) |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1879-0828 |
EndPage | 328 |
ExternalDocumentID | oai_HAL_hal_03287859v1 10_1016_S0953_6205_02_00085_7 12144912 S0953620502000857 |
Genre | Journal Article |
GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1~. 1~5 29G 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAXUO ABBQC ABJNI ABLJU ABLVK ABMAC ABMZM ABXDB ABYKQ ACDAQ ACIUM ACRLP ADBBV ADEZE AEBSH AEKER AENEX AEVXI AFCTW AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM LCYCR M41 MO0 N9A O-L O9- OAUVE OD. OO~ OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SCC SDF SDG SEL SES SEW SPCBC SSH SSZ T5K Z5R ~G- AAXKI AFJKZ AKRWK NPM AAYXX CITATION 7X8 1XC |
ID | FETCH-LOGICAL-c455t-79ecce58d894f9b9429ae49f95a0db0c7c93096be4ae0aaa3ff55e8af0b180533 |
ISSN | 0953-6205 |
IngestDate | Tue Oct 15 15:40:00 EDT 2024 Fri Oct 25 21:25:18 EDT 2024 Thu Sep 26 18:28:23 EDT 2024 Sat Sep 28 07:35:55 EDT 2024 Fri Feb 23 02:30:19 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Sepsis syndrome Drug-induced agranulocytosis Infections Antibiotics G-CSF Fever |
Language | English |
License | Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c455t-79ecce58d894f9b9429ae49f95a0db0c7c93096be4ae0aaa3ff55e8af0b180533 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 12144912 |
PQID | 1859375327 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | hal_primary_oai_HAL_hal_03287859v1 proquest_miscellaneous_1859375327 crossref_primary_10_1016_S0953_6205_02_00085_7 pubmed_primary_12144912 elsevier_sciencedirect_doi_10_1016_S0953_6205_02_00085_7 |
PublicationCentury | 2000 |
PublicationDate | 2002-Aug |
PublicationDateYYYYMMDD | 2002-08-01 |
PublicationDate_xml | – month: 08 year: 2002 text: 2002-Aug |
PublicationDecade | 2000 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | European journal of internal medicine |
PublicationTitleAlternate | Eur J Intern Med |
PublicationYear | 2002 |
Publisher | Elsevier B.V Elsevier |
Publisher_xml | – name: Elsevier B.V – name: Elsevier |
References | Beauchesne, Shalansky (BIB23) 1999; 19 Hunault, Dombret, Gardin, Rio, Hermine, Brice (BIB20) 1995; 9 Andrès, Kurtz, Offner, Grunenberger, Weber, Kaltenbach (BIB4) 1998; 74 Andrès, Kurtz, Perrin, Dufour, Schlienger, Maloisel (BIB9) 2001; 94 Sprikkelman, de Wolf, Vellenga (BIB22) 1994; 8 van der Klauw, Goudsmit, Halie, van’t Veer, Herings, Wilson (BIB17) 1999; 159 Maloisel, Lioure, Weber, Voillat, staub, Offner (BIB12) 1995; 37 Andrès, Maloisel (BIB15) 1999; 159 Kaufman, Kelly, Levy, Shapiro (BIB10) 1993; 2 van der Klauw, Wilson, Stricker (BIB18) 1998; 57 Schultz (BIB1) 1922; 48 Andrès, Kurtz, Martin, Kaltenbach, Alt, Weber (BIB25) 2002; 112 Bénichou, Solal-Celigny (BIB11) 1993; 33 Paitel, Stockemer, Dorvaux, Witz, Guerci, Lederlin (BIB3) 1995; 16 (BIB13) 1996; 14 Shapiro, Issaragrisil, Kaufman, Anderson, Chansung, Thamprasit (BIB16) 1999; 60 De Lannoy, Ravoet (BIB21) 1995; 9 Kurtz, Andrès, Maloisel, Kurtz-Illig, Heitz, Sibilia (BIB7) 1999; 28 Dale (BIB14) 1990 Vial, Pofilet, Pham, Payen, Evreux (BIB6) 1996; 51 Fukata, Kuma, Sugawara (BIB24) 1999; 9 Fattinger, Roos, Vergeres, Holenstein, Kind, Masche (BIB19) 2000; 49 Julia, Olono, Bueno, Revilla, Rosselo, Petit (BIB5) 1991; 79 Andrès, Maloisel, Kurtz, Vinzio, Sibilia, Schlienger (BIB8) 2000; 21 Strom, Carson, Schinnar, Snyder, Shaw (BIB2) 1992; 152 Shapiro (10.1016/S0953-6205(02)00085-7_BIB16) 1999; 60 Julia (10.1016/S0953-6205(02)00085-7_BIB5) 1991; 79 Kurtz (10.1016/S0953-6205(02)00085-7_BIB7) 1999; 28 Andrès (10.1016/S0953-6205(02)00085-7_BIB15) 1999; 159 Strom (10.1016/S0953-6205(02)00085-7_BIB2) 1992; 152 Andrès (10.1016/S0953-6205(02)00085-7_BIB4) 1998; 74 Andrès (10.1016/S0953-6205(02)00085-7_BIB9) 2001; 94 Maloisel (10.1016/S0953-6205(02)00085-7_BIB12) 1995; 37 Bénichou (10.1016/S0953-6205(02)00085-7_BIB11) 1993; 33 De Lannoy (10.1016/S0953-6205(02)00085-7_BIB21) 1995; 9 Beauchesne (10.1016/S0953-6205(02)00085-7_BIB23) 1999; 19 Fattinger (10.1016/S0953-6205(02)00085-7_BIB19) 2000; 49 Paitel (10.1016/S0953-6205(02)00085-7_BIB3) 1995; 16 Vial (10.1016/S0953-6205(02)00085-7_BIB6) 1996; 51 Andrès (10.1016/S0953-6205(02)00085-7_BIB8) 2000; 21 Dale (10.1016/S0953-6205(02)00085-7_BIB14) 1990 Kaufman (10.1016/S0953-6205(02)00085-7_BIB10) 1993; 2 van der Klauw (10.1016/S0953-6205(02)00085-7_BIB17) 1999; 159 Fukata (10.1016/S0953-6205(02)00085-7_BIB24) 1999; 9 Schultz (10.1016/S0953-6205(02)00085-7_BIB1) 1922; 48 Andrès (10.1016/S0953-6205(02)00085-7_BIB25) 2002; 112 Sprikkelman (10.1016/S0953-6205(02)00085-7_BIB22) 1994; 8 Hunault (10.1016/S0953-6205(02)00085-7_BIB20) 1995; 9 (10.1016/S0953-6205(02)00085-7_BIB13) 1996; 14 van der Klauw (10.1016/S0953-6205(02)00085-7_BIB18) 1998; 57 |
References_xml | – volume: 79 start-page: 366 year: 1991 end-page: 372 ident: BIB5 article-title: Drug-induced agranulocytosis: prognostic factors in a serie of 168 episodes publication-title: Br J Hematol contributor: fullname: Petit – volume: 37 start-page: 114a year: 1995 ident: BIB12 article-title: Utilisation du G- et du GM-CSF dans les agranulocytoses médicamenteuses publication-title: Nouv Rev Fr Hematol contributor: fullname: Offner – volume: 19 start-page: 299 year: 1999 end-page: 305 ident: BIB23 article-title: Nonchemotherapy drug-induced agranulocytosis: a review of 118 patients treated with colony-stimulating factors publication-title: Pharmacotherapy contributor: fullname: Shalansky – volume: 2 start-page: 525 year: 1993 end-page: 529 ident: BIB10 article-title: The drug etiology of agranulocytosis: an uptade of the International Agranulocytosis and Aplastic Anemia Study publication-title: Pharmacoepidemiol Drug Safety contributor: fullname: Shapiro – volume: 94 start-page: 423 year: 2001 end-page: 428 ident: BIB9 article-title: The use of haematopoietic growth factors in antithyroid-related drug-induced agranulocytosis: a report of 20 patients publication-title: Q J Med contributor: fullname: Maloisel – volume: 8 start-page: 2031 year: 1994 end-page: 2036 ident: BIB22 article-title: The application of hematopoietic growth factors in drug-induced agranulocytosis: a review of 70 cases publication-title: Leukemia contributor: fullname: Vellenga – volume: 60 start-page: 573 year: 1999 end-page: 577 ident: BIB16 article-title: Agranulocytosis in Bangkok, Thailand: a predominantly drug-induced disease with an unusually low incidence. Aplastic Anemia Study Group publication-title: Am J Trop Med Hyg contributor: fullname: Thamprasit – volume: 9 start-page: 1286 year: 1995 end-page: 1287 ident: BIB20 article-title: Hematopoietic growth factors in drug-induced agranulocytosis publication-title: Leukemia contributor: fullname: Brice – volume: 9 start-page: 1289 year: 1995 end-page: 1290 ident: BIB21 article-title: Hematopoietic growth factors in drug-induced agranulocytosis publication-title: Leukemia contributor: fullname: Ravoet – volume: 48 start-page: 1495 year: 1922 end-page: 1497 ident: BIB1 article-title: Uber eigenartige Halserkrankungen publication-title: Dtsch Med Wochenschr contributor: fullname: Schultz – volume: 112 start-page: 460 year: 2002 end-page: 464 ident: BIB25 article-title: Non-chemotherapy drug-induced agranulocytosis in elderly patients: the effects of granulocyte-colony stimulating factor publication-title: Am J Med contributor: fullname: Weber – volume: 16 start-page: 495 year: 1995 end-page: 499 ident: BIB3 article-title: Agranulocytoses aiguës médicamenteuses. Etude clinique à propos de 30 patients et évolution des étiologies sur 2 décennies publication-title: Rev Med Interne contributor: fullname: Lederlin – volume: 152 start-page: 1475 year: 1992 end-page: 1480 ident: BIB2 article-title: Descriptive epidemiology of agranulocytosis publication-title: Arch Intern Med contributor: fullname: Shaw – volume: 159 start-page: 369 year: 1999 end-page: 374 ident: BIB17 article-title: A population-based case-cohort study of drug-associated agranulocytosis publication-title: Arch Intern Med contributor: fullname: Wilson – volume: 74 start-page: 1105 year: 1998 end-page: 1110 ident: BIB4 article-title: Agranulocytoses médicamenteuses: expérience du CHU de Strasbourg publication-title: Semin Hop Paris contributor: fullname: Kaltenbach – volume: 51 start-page: 508 year: 1996 end-page: 515 ident: BIB6 article-title: Agranulocytoses aiguës médicamenteuses: expérience du centre Régional de Pharmacovigilance de Lyon sur 7 ans publication-title: Thérapie contributor: fullname: Evreux – volume: 57 start-page: 206 year: 1998 end-page: 211 ident: BIB18 article-title: Drug-associated agranulocytosis: 20 years of reporting in The Netherlands (1974–1994) publication-title: Am J Hematol contributor: fullname: Stricker – volume: 28 start-page: 325 year: 1999 end-page: 326 ident: BIB7 article-title: Drug-induced agranulocytosis in older people. A case series of 25 patients publication-title: Age Ageing contributor: fullname: Sibilia – volume: 33 start-page: 257 year: 1993 end-page: 262 ident: BIB11 article-title: Standardization of definitions and criteria for causality assessment of adverse drug reactions. Drug-induced blood cytopenias: report of an international consensus meeting publication-title: Nouv Rev Fr Hematol contributor: fullname: Solal-Celigny – volume: 159 start-page: 2366 year: 1999 end-page: 2367 ident: BIB15 article-title: Drug-associated agranulocytosis: experience at Strasbourg Teaching Hospital publication-title: Arch Intern Med contributor: fullname: Maloisel – volume: 21 start-page: 580 year: 2000 end-page: 585 ident: BIB8 article-title: Les facteurs de croissance hématopoı̈étique ont-il un intérêt dans le traitement des agranulocytoses médicamenteuses publication-title: Rev Med Interne contributor: fullname: Schlienger – volume: 14 start-page: 1957 year: 1996 end-page: 1960 ident: BIB13 article-title: Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guide-lines publication-title: J Clin Oncol – start-page: 812 year: 1990 end-page: 817 ident: BIB14 article-title: Neutropenia publication-title: Hematology contributor: fullname: Dale – volume: 49 start-page: 158 year: 2000 end-page: 167 ident: BIB19 article-title: Epidemiology of drug exposure and adverse drug reactions in two swiss departments of Internal Medicine publication-title: Br J Clin Pharmacol contributor: fullname: Masche – volume: 9 start-page: 29 year: 1999 end-page: 31 ident: BIB24 article-title: Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study publication-title: Thyroı̈d contributor: fullname: Sugawara – volume: 9 start-page: 1286 year: 1995 ident: 10.1016/S0953-6205(02)00085-7_BIB20 article-title: Hematopoietic growth factors in drug-induced agranulocytosis publication-title: Leukemia contributor: fullname: Hunault – volume: 33 start-page: 257 year: 1993 ident: 10.1016/S0953-6205(02)00085-7_BIB11 article-title: Standardization of definitions and criteria for causality assessment of adverse drug reactions. Drug-induced blood cytopenias: report of an international consensus meeting publication-title: Nouv Rev Fr Hematol contributor: fullname: Bénichou – volume: 8 start-page: 2031 year: 1994 ident: 10.1016/S0953-6205(02)00085-7_BIB22 article-title: The application of hematopoietic growth factors in drug-induced agranulocytosis: a review of 70 cases publication-title: Leukemia contributor: fullname: Sprikkelman – volume: 16 start-page: 495 year: 1995 ident: 10.1016/S0953-6205(02)00085-7_BIB3 article-title: Agranulocytoses aiguës médicamenteuses. Etude clinique à propos de 30 patients et évolution des étiologies sur 2 décennies publication-title: Rev Med Interne doi: 10.1016/0248-8663(96)80745-4 contributor: fullname: Paitel – volume: 159 start-page: 2366 year: 1999 ident: 10.1016/S0953-6205(02)00085-7_BIB15 article-title: Drug-associated agranulocytosis: experience at Strasbourg Teaching Hospital publication-title: Arch Intern Med doi: 10.1001/archinte.159.19.2366 contributor: fullname: Andrès – volume: 28 start-page: 325 year: 1999 ident: 10.1016/S0953-6205(02)00085-7_BIB7 article-title: Drug-induced agranulocytosis in older people. A case series of 25 patients publication-title: Age Ageing doi: 10.1093/ageing/28.3.325 contributor: fullname: Kurtz – volume: 37 start-page: 114a year: 1995 ident: 10.1016/S0953-6205(02)00085-7_BIB12 article-title: Utilisation du G- et du GM-CSF dans les agranulocytoses médicamenteuses publication-title: Nouv Rev Fr Hematol contributor: fullname: Maloisel – volume: 57 start-page: 206 year: 1998 ident: 10.1016/S0953-6205(02)00085-7_BIB18 article-title: Drug-associated agranulocytosis: 20 years of reporting in The Netherlands (1974–1994) publication-title: Am J Hematol doi: 10.1002/(SICI)1096-8652(199803)57:3<206::AID-AJH4>3.0.CO;2-Z contributor: fullname: van der Klauw – volume: 9 start-page: 29 year: 1999 ident: 10.1016/S0953-6205(02)00085-7_BIB24 article-title: Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study publication-title: Thyroı̈d doi: 10.1089/thy.1999.9.29 contributor: fullname: Fukata – volume: 94 start-page: 423 year: 2001 ident: 10.1016/S0953-6205(02)00085-7_BIB9 article-title: The use of haematopoietic growth factors in antithyroid-related drug-induced agranulocytosis: a report of 20 patients publication-title: Q J Med doi: 10.1093/qjmed/94.8.423 contributor: fullname: Andrès – volume: 2 start-page: 525 year: 1993 ident: 10.1016/S0953-6205(02)00085-7_BIB10 article-title: The drug etiology of agranulocytosis: an uptade of the International Agranulocytosis and Aplastic Anemia Study publication-title: Pharmacoepidemiol Drug Safety doi: 10.1002/pds.2630020706 contributor: fullname: Kaufman – volume: 60 start-page: 573 year: 1999 ident: 10.1016/S0953-6205(02)00085-7_BIB16 article-title: Agranulocytosis in Bangkok, Thailand: a predominantly drug-induced disease with an unusually low incidence. Aplastic Anemia Study Group publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.1999.60.573 contributor: fullname: Shapiro – volume: 19 start-page: 299 year: 1999 ident: 10.1016/S0953-6205(02)00085-7_BIB23 article-title: Nonchemotherapy drug-induced agranulocytosis: a review of 118 patients treated with colony-stimulating factors publication-title: Pharmacotherapy doi: 10.1592/phco.19.4.299.30941 contributor: fullname: Beauchesne – volume: 112 start-page: 460 year: 2002 ident: 10.1016/S0953-6205(02)00085-7_BIB25 article-title: Non-chemotherapy drug-induced agranulocytosis in elderly patients: the effects of granulocyte-colony stimulating factor publication-title: Am J Med doi: 10.1016/S0002-9343(02)01064-1 contributor: fullname: Andrès – volume: 74 start-page: 1105 year: 1998 ident: 10.1016/S0953-6205(02)00085-7_BIB4 article-title: Agranulocytoses médicamenteuses: expérience du CHU de Strasbourg publication-title: Semin Hop Paris contributor: fullname: Andrès – volume: 159 start-page: 369 year: 1999 ident: 10.1016/S0953-6205(02)00085-7_BIB17 article-title: A population-based case-cohort study of drug-associated agranulocytosis publication-title: Arch Intern Med doi: 10.1001/archinte.159.4.369 contributor: fullname: van der Klauw – start-page: 812 year: 1990 ident: 10.1016/S0953-6205(02)00085-7_BIB14 article-title: Neutropenia contributor: fullname: Dale – volume: 48 start-page: 1495 year: 1922 ident: 10.1016/S0953-6205(02)00085-7_BIB1 article-title: Uber eigenartige Halserkrankungen publication-title: Dtsch Med Wochenschr contributor: fullname: Schultz – volume: 21 start-page: 580 year: 2000 ident: 10.1016/S0953-6205(02)00085-7_BIB8 article-title: Les facteurs de croissance hématopoı̈étique ont-il un intérêt dans le traitement des agranulocytoses médicamenteuses publication-title: Rev Med Interne doi: 10.1016/S0248-8663(00)80002-8 contributor: fullname: Andrès – volume: 9 start-page: 1289 year: 1995 ident: 10.1016/S0953-6205(02)00085-7_BIB21 article-title: Hematopoietic growth factors in drug-induced agranulocytosis publication-title: Leukemia contributor: fullname: De Lannoy – volume: 49 start-page: 158 year: 2000 ident: 10.1016/S0953-6205(02)00085-7_BIB19 article-title: Epidemiology of drug exposure and adverse drug reactions in two swiss departments of Internal Medicine publication-title: Br J Clin Pharmacol doi: 10.1046/j.1365-2125.2000.00132.x contributor: fullname: Fattinger – volume: 79 start-page: 366 year: 1991 ident: 10.1016/S0953-6205(02)00085-7_BIB5 article-title: Drug-induced agranulocytosis: prognostic factors in a serie of 168 episodes publication-title: Br J Hematol doi: 10.1111/j.1365-2141.1991.tb08042.x contributor: fullname: Julia – volume: 51 start-page: 508 year: 1996 ident: 10.1016/S0953-6205(02)00085-7_BIB6 article-title: Agranulocytoses aiguës médicamenteuses: expérience du centre Régional de Pharmacovigilance de Lyon sur 7 ans publication-title: Thérapie contributor: fullname: Vial – volume: 152 start-page: 1475 year: 1992 ident: 10.1016/S0953-6205(02)00085-7_BIB2 article-title: Descriptive epidemiology of agranulocytosis publication-title: Arch Intern Med doi: 10.1001/archinte.1992.00400190095018 contributor: fullname: Strom – volume: 14 start-page: 1957 year: 1996 ident: 10.1016/S0953-6205(02)00085-7_BIB13 article-title: Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guide-lines publication-title: J Clin Oncol doi: 10.1200/JCO.1996.14.6.1957 |
SSID | ssj0017003 |
Score | 1.8516675 |
Snippet | Background: The present study reports a monocentric experience of 90 drug-induced agranulocytosis cases and discusses their management, in particular the role... BACKGROUND: The present study reports a monocentric experience of 90 drug-induced agranulocytosis cases and discusses their management, in particular the role... |
SourceID | hal proquest crossref pubmed elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 324 |
SubjectTerms | Antibiotics Drug-induced agranulocytosis Fever G-CSF Human health and pathology Infections Life Sciences Sepsis syndrome |
Title | Modern management of non-chemotherapy drug-induced agranulocytosis: a monocentric cohort study of 90 cases and review of the literature |
URI | https://dx.doi.org/10.1016/S0953-6205(02)00085-7 https://www.ncbi.nlm.nih.gov/pubmed/12144912 https://search.proquest.com/docview/1859375327 https://hal.science/hal-03287859 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zj9MwELa6uxLiBXFTLhnEA6gy61y1zVsFRWU5XnaR9i1yUmeptG1Q2yDtL-BvM2O7cbarikPiJY0sZ-x0vozHnouQF9IolVYqYXDlLNXwzamoUKxIdMIVQCazvjmTY_HlVL4bp-Neb1MTNLT9V05DG_AaI2f_gtstUWiAe-A5XIHrcP0jvvviZvPWrcW6atQLBtyZ-3Cri8F02Zwx2I43aP7XZ7BgNbCqXazr1Wzl4p9hwrX13JyVA6yiu1y7VLRITvFBCaufS-8cgl9Qhz1v0zTvPPPvJKqw99vmffSxtPZ76UIl5vAujQn-i_q8xhpRTu12hv6p-1nOyo5pylaqHRzBsGybxkd0ElgU2tXBcnaBywcgcet-50_lrkTm-OPNhA1j7izmxgl3KRTDlH2XpH_SQXnWEeWJi-32WkHinrqy4Lizj-N2ONgWYEpbZXVZJsIq2_o-2r7Ylce2k9gjBzFISRDSB6MP49Oj1ggmuC3s3dIOAWiHYcCXPH7lB9ulWu19Qx_fXRsoq0id3CQ3_A6Ijhx0b5GeWdwm1z57ENwhPx2CaUAwrSu6jWDaRTDdQvAbqmkHv9Thl1r8IjHFqcUvBfxSh19sBtI04Pcu-fp-fPJ2wny5EFamWbZmQoE4MpmcSpQ-hQJNS5tUVSrTfFrwUpQKxM-wMKk2XGudVFWWGakrXkQSQ9LvkX14GfOAUGVkHBklKuxdDIey0lFSwvZA6EqarOyT15t_Ov_ussLkwV0SWJMja3Ie55Y1uegTueFH7lVbp7LmAKTfPfoc-NcOg-ngJ6NPObZhLkwhM_Uj6pNnG_bmsD6g0U8vTN2s8ggTGoosiYHQfcf3MGXMl6ii-OG_z-4RuR6-ycdkf71szBOyt5o2Tz2cfwGjxOR9 |
link.rule.ids | 230,315,782,786,887,27933,27934 |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Modern+management+of+non-chemotherapy+drug-induced+agranulocytosis%3A+a+monocentric+cohort+study+of+90+cases+and+review+of+the+literature&rft.jtitle=European+journal+of+internal+medicine&rft.au=Andr%C3%A8s%2C+Emmanuel&rft.au=Maloisel%2C+Fr%C3%A9d%C3%A9ric&rft.au=Kurtz%2C+Jean-Emmanuel&rft.au=Kaltenbach%2C+Georges&rft.date=2002-08-01&rft.pub=Elsevier+B.V&rft.issn=0953-6205&rft.eissn=1879-0828&rft.volume=13&rft.issue=5&rft.spage=324&rft.epage=328&rft_id=info:doi/10.1016%2FS0953-6205%2802%2900085-7&rft.externalDocID=S0953620502000857 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0953-6205&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0953-6205&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0953-6205&client=summon |